ECM
NBIX icon

ETrade Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

ETrade Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$215K Buy
2,238
+501
+29% +$58K ﹤0.01% 803
2020
Q2 		$212K Buy
+1,737
New +$192K ﹤0.01% 762
2018
Q4 		– Sell
-4,535
Closed -$558K – 787
2018
Q3 		$558K Buy
+4,535
New +$515K 0.02% 517

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

ETrade Capital Management's NBIX Position: Q3 2020 in Review

ETrade Capital Management increased its Neurocrine Biosciences (NBIX) stake by 29% in Q3 2020, buying an estimated $58K and bringing the position to 2,238 shares worth $215K. The position accounts for ﹤0.01% of the portfolio, ranked #803.

ETrade Capital Management first reported a position in NBIX in Q3 2018 and has held it in 3 quarters since. The position peaked at $558K in Q3 2018. 418 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

  • ETrade Capital Management held 2,238 shares of Neurocrine Biosciences worth $215K as of Q3 2020.
  • ETrade Capital Management bought 501 Neurocrine Biosciences shares in Q3 2020, an estimated $58K.
  • Neurocrine Biosciences made up ﹤0.01% of ETrade Capital Management's portfolio in Q3 2020, its #803 holding.
  • ETrade Capital Management first reported a position in Neurocrine Biosciences in Q3 2018 and has held it in 3 quarters since.
  • ETrade Capital Management's Neurocrine Biosciences position peaked at $558K in Q3 2018.
  • 418 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.